. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
. The NKG2D-CAR construct binds 8 different ligands in an MHC-independent fashion expressed by cancer cells of diverse origins 3, 7, 8 . Because the ligands for the NKG2D receptor are absent or expressed at very low levels in normal tissues 1, 9 , specificity for tumors is considered to be high. In agreement, we previously demonstrated no recognition of normal peripheral blood mononuclear cells nor healthy bone marrow from healthy patients by CYAD-01 in vitro 10 . Preclinical studies have
shown that CYAD-01 mediates potent anti-tumor activity against both hematological and solid tumors without the requirement of prior lymphodepleting chemotherapy 3, 6 . Single intravenous administration of low dose autologous CYAD-01 (maximum 3x10 7 flat dose), We report here the case of a 52 years old male with r/r AML. The patient had +8/del (7) . CYAD-01 was well tolerated with non-related grade 1 adverse events without cytokine release syndrome (CRS) or neurotoxic effects. BM evaluation at day +28 following 2 CYAD-01 infusions showed morphologic leukemia-free state (MLFS, 2% blasts) with normocellularity and trilineage hematopoiesis, which was confirmed at day +56 BM with del(7q) by FISH at 7% (Fig. 1C) . Serial next-generation sequencing (NGS) of BM-MNCs showed persistent DNMT3A R882H mutation, but also identified a new IDH2 R172K mutation. The patient had resolution of symptoms with improved hematopoiesis, which continued to improve until the patient was treated with an allo-HSCT on day +97 post CYAD-01 (Fig. 1D) . At disease evaluation 100 days post allo-HSCT (day +197 post CYAD-01), the patient achieved a complete molecular remission by serial NGS with 100% donor chimerism (Fig. 1D ). To date, the patient has maintained a CR 6 months from allo-HSCT and 9 months following initial CYAD-01 infusion. ( Fig. S1A and S1B ). Immunohistochemistry (IHC) analysis on the baseline BM taken showed positive staining of foci of neoplastic cells for all NKG2DL assessed (Fig S2) , with the strongest expression for MICA/MICB (Fig. 2B ). Of note, there was no NKG2DL expression on the non-neoplastic BM cells. Finally, it is important to mention no detectable level of the transgene was evidenced at day +1, +4 and +32 post-injection, using a Vector copy number (VCN) qPCR-based assay, suggesting poor in vivo expansion and persistence of the injected cell product.
CAR therapy has brought forth a paradigm change in the management of refractory chemoresistant B-cell leukemia 12 . However, the choice of target in AML has been challenging due Page 5 of 9
to their normal expression on hematopoietic stem cells leading to potential irreversible hematopoietic toxicity 13 . Thus, current CAR-T strategies in AML either require a backup allo-HSCT or unproven shut-off mechanisms 14 . In contrast, NKG2DL are upregulated in transformed cells with minimal expression in normal tissues 1 . This was confirmed by the absence of significant adverse events of CYAD-01 in this AML patient and no Grade 3 or above adverse events related to treatment in any of the AML patients enrolled in the THINK trial up to now. This is of critical clinical importance given CD19 specific CAR-T cell therapies with grade 5 toxicities including CRS, neurotoxicity and on-target off-tumor toxicity against normal cells 15 . The low toxicity, with clinical activity, observed in this patient is most probably related to multiple factors: (i) CYAD-01 cells demonstrate only short-term persistence and low proliferation post-infusion, (ii) the chimeric CYAD-01 construct consists entirely of human sequences, with an entirely native extracellular domain not expected to induce the anaphylaxis reactions observed with other CAR-Ts using scFv from murine origin 16 , and (iii) the absence of previous lymphodepleting chemotherapy.
While reduction of blasts occurred in AML patients treated with LeY-specific CAR-Ts was also previously reported, the clinical response could not be entirely attributed to the activity of the CAR-T since these patients were in morphological CR after reinduction with fludarabine prior to CAR-T administration 17 . In the only published r/r AML case report evaluating the CD33-specific CAR-Ts without conditioning therapy, a 2-weeks transient decrease in blast count was reported in the context of grade 4 chills, fevers and transient hyperbilirubinemia, but with a rapid disease progression, suggesting tumor escape mechanism 18 . Of clinical interest in the setting of MLFS and blood counts approaching complete remission at the time of allo-HSCT, the patient had identification of a IDH2 mutation that was not present prior to treatment. This suggests that there can be heterogeneity of NKG2D ligand expression that is Page 6 of 9 dependent on the underlying molecular architecture. This is supported by a recent study in IDH mutant gliomas where NKG2D ligands were down-regulated 19 . Future study is required to further investigate molecular drivers of NKG2D ligand expression in AML in order to further augment efficacy of CYAD-01. In summary, we report the first objective response to CAR-T in r/r AML using CYAD-01 without preconditioning chemotherapy and with no significant toxicities, highlighting the potential of targeting NKG2DL in AML. ULBP3. In addition, a sample of each was prepared applying standard hematoxylin and eosin (H&E) staining (data not shown). All samples were examined and graded by light microscopy.
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Representative stainings of ULBP1 (A), ULBP2/5/6 (B) and ULBP3 (C). It has to be noted that ULBP2/5/6 are predominantly stained in the nucleus and that ULBP1, ULBP3 and MICA/B (Fig. 2B ) display cytoplasmic staining as well.
